about
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokersMolecular proteomics imaging of tumor interfaces by mass spectrometry.Detection of sexually transmitted infection and human papillomavirus in negative cytology by multiplex-PCR.Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests.Molecular Testing of Lung CancersScreening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.LAMC2 enhances the metastatic potential of lung adenocarcinoma.Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.MET Exon 14 Skipping in Non-Small Cell Lung Cancer.Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study GroupGenomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negativeClinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditionsImage analysis of peripheral compression artefacts of ThinPrep(®) liquid-based cytology preparations.Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).Transforming growth factor-beta 1 in humidifier disinfectant-associated children's interstitial lung disease.Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisBiology of invasive mucinous adenocarcinoma of the lung.KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression.TGF-β1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity.Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis.Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways.A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.Malignant lymphoma arising in cardiac myxoma, presenting with peripheral arterial emboli.
P50
Q27851960-BC62A680-5B6A-4A23-828F-F47F5FADC2CEQ28383535-3DB8CACC-F492-47D8-AE54-DC0B2BA39924Q33509852-799E4B95-AB52-41F1-903F-C7716087F9AEQ33709675-61EBF017-BCF8-437A-98C9-112B42FEEAEEQ33729699-140E77E9-2BF5-4296-9872-38EC4AB79476Q33729715-095F2904-5291-47A5-A488-F46098BDF656Q33945982-649C5F7B-06A3-4444-A7ED-935CF4E9D9D8Q35233122-1583CFD1-1DE6-435C-A8A6-91C6D0B66A1DQ35829871-305A22EA-6110-44CF-BBF3-71DE522C76EDQ35958288-083944B3-40BD-4062-8A82-0D83D64327ADQ36266449-D91771A8-0F53-4B57-AEF6-4BCB14D8E043Q36788312-612CCE9C-5CF1-4BE3-AC58-3E3B791BC04DQ36824366-791EA20B-2165-4C21-BBC6-3A7B04E94EA3Q37269251-FCB0E21A-323B-492F-B02A-EA68C6E50F77Q37349315-6CA1D4E5-8CAA-4253-9B4C-B1632158911FQ37631021-52F58E9B-C966-4D50-8705-41A52AA6BBA1Q37943020-3EDA6AF2-5F9B-418B-8517-93F3B04E8EDBQ38087392-F7C0507A-754C-4652-BD54-F796890731EFQ38402702-C15103CF-2B84-4EF9-9391-D8C085884A7CQ38417869-B094E2C5-0B6E-4BB9-85A4-2FB7E040320AQ38427508-49FFE3D1-0F00-4B29-B812-B9B32323B02BQ38705330-11B947EA-7A48-46D9-8DB6-CD9294AEE5AEQ38820678-88113A4E-C982-4CE8-8487-03E5640E7DE3Q39345220-EBD7E452-B313-4A66-B28C-34C08BCC1A71Q40709158-D18B28AA-5321-4490-A1E3-C9F2983599B6Q40897280-08A31199-C66F-4C65-88B9-D1908D618075Q41641787-7ECB68A0-2E37-44BD-AE55-1A33DE4A14B0Q42241266-46399AEE-6233-4C89-9841-672C80C615ECQ42371507-F0406871-C385-4CEB-83FC-6FA604F15077Q43874020-55FD6697-6652-45A9-A3FD-E2980187E952Q44041984-58521F98-CE91-40F2-A1F7-4C868F45CA76Q44092484-7A16AE08-25E3-4535-BC81-BF4506D54D73Q44337507-5DC2B59A-30F2-433D-86C7-F419CD159FACQ45174196-4606C817-48D0-4CD9-B713-79C2D90E6825Q46178018-D6B89C8F-4D94-4644-BB35-16FE5CB77F38Q46204893-95596994-875F-4DE0-8755-E39D47F2F93FQ46369266-D21E4E28-D440-459A-BA2C-FA89F5304816Q47105638-AAB3FDF8-23D3-41CD-98F4-89970342B3A2Q48683050-982C8CAF-3BBE-434A-A1C6-BE470D585994Q49886499-35126B8E-15CB-43EE-9343-966944E15DC3
P50
description
researcher ORCID ID = 0000-0002-5718-3624
@en
wetenschapper
@nl
name
Hyo Sup Shim
@ast
Hyo Sup Shim
@en
Hyo Sup Shim
@es
Hyo Sup Shim
@nl
type
label
Hyo Sup Shim
@ast
Hyo Sup Shim
@en
Hyo Sup Shim
@es
Hyo Sup Shim
@nl
prefLabel
Hyo Sup Shim
@ast
Hyo Sup Shim
@en
Hyo Sup Shim
@es
Hyo Sup Shim
@nl
P106
P31
P496
0000-0002-5718-3624